The global blood glucose meters industry size was valued at USD 15.80 billion in 2022 and will register a robust CAGR of around 7.3% from 2023 to 2030
#cgm
#bgm
DarioHealth Corp. announced today an agreement with Dexcom to integrate its market-leading CGMs, into Dario's multi-chronic condition platform. This agreement enables the integration of data from Dexcom CGMs directly into Dario's metabolic solution, making it easy for people using the wearable device to benefit from Dario's highly personalized support.
#connected device
#cgm
#mobile app
DigiBete launched the Type 1 Diabetes clinical trial finder on the DigiBete website which gives users access to a wide variety of trials for all ages.
DexCom, Inc today unveiled the company’s second Super Bowl commercial, which announces the US launch of its next-generation Dexcom G7 CGM System. The ad, which will run during the second quarter of Super Bowl LVII on Feb. 12, 2023, stars multi-platinum recording artist, songwriter, actor and philanthropist, Nick Jonas.
#cgm
the global market for Glucose Monitoring Devices estimated at US$13.1 Billion in the year 2022, is projected to reach a revised size of US$19.2 Billion by 2030, growing at aCAGR of 4.8% over the period 2022-2030. Self-Monitoring Devices, one of the segments analyzed in the report, is projected to record 4% CAGR and reach US$11.3 Billion by the end of the analysis period.
#cgm
#bgm
Blue Shield of California today announced an expanded partnership with Virta Health, the leader in type 2 diabetes reversal, as Virta joins the nonprofit health plan's statewide provider network for 2023. Virta is the first digital diabetes solution to be fully covered for eligible members under Blue Shield's benefits program.
#insurance
#virtual care
#telehealth
Eli Lilly and Company (NYSE: LLY) will participate in the SVB Securities Global Biopharma Conference on Thursday, Feb. 16, 2023. Ilya Yuffa, executive vice president and president, Lilly International, will participate in a virtual fireside chat at 12 p.m., Eastern time.
Tidepool announced recently that the FDA cleared its Tidepool Loop, a “do-it-yourself,” (DIY) automated insulin delivery (AID) system. Tidepool designed Tidepool Loop for the management of type 1 diabetes in people with diabetes six years of age or older. It has compatibility with the Apple Watch, according to the company’s website. According to a news release, the algorithm works with compatible integrated CGMs and alternate controller-enabled (ACE) pumps.
#closed loop
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced that management will participate in the Cowen 43nd Annual Healthcare Conference, which is being held March 6-8, 2023, at the Boston Marriott Copley Place in Boston, Massachusetts. Erez Raphael, Chief Executive Officer, and Rick Anderson, President, will participate in a fireside chat on Monday, March 6th, from 10:30 – 11:00 AM ET.
Insulet Corporation today announced financial results for the three months and full year ended December 31, 2022. Full year 2022 revenue of $1.3 billion, up 18.8%, or 22.5% in constant currency, compared to $1.1 billion in the prior year, exceeds the guidance range of 18% to 19% in constant currency. Total Omnipod revenue in 2022 of $1.2 billion increased by 23.4%, or 27.4% in constant currency. Fourth quarter 2022 revenue of $369.7 million, up 20.1%, or 23.7% in constant currency, compared to $307.7 million in the prior year, exceeds the guidance range of 11% to 14% in constant currency. Total Omnipod revenue in Q4 of $366.4 million increased by 32.8%, or 36.8% in constant currency